

SAFETY DATA SHEET

SECTION 1: IDENTIFICATION

Decitabine for Injection Product Name: Manufacturer Name: Shilpa Medicare Limited Formulation Unit Address:

Plot No: S20 to S24A, Green Industrial Park, Polepally (V), Jadcherla (M),

Mahaboobnagar Dist., Telangana, 509301

India

General Phone Number: +91-08532 - 238704 +91-08532 - 238876 General Fax Number: Emergency Phone Number: +91-8532-235876 Distributor Name: Fresenius Kabi USA, LLC Address: Three Corporate Drive Lake Zurich, Illinois 60047

General Phone Number: (847) 550-2300 Customer Service Phone

Number:

(888) 386-1300

Health Issues Information: (800) 551-7176 SDS Creation Date: May 30, 2019 SDS Revision Date: October 14, 2019

SECTION 2: HAZARD(S) IDENTIFICATION

GHS Pictograms:





Signal Word: DANGERI

Acute toxicity - Oral, Category 4 Acute toxicity - Dermal, Category 4 GHS Class:

Acute toxicity - Inhalation, Category 4 Skin irritation, Category 2 Eye irritation, Category 2A

Germ cell mutagenicity, Category 2
Reproductive toxicity, Category 1B
Specific target organ toxicity - single exposure, Category 3 (Respiratory system)

Hazard Statements: Harmful if inhaled. May cause respiratory irritation. Suspected of causing genetic defects. May damage

fertility or the unborn child. Causes serious eye and skin irritation. Harmful if swallowed or if inhaled Harmful in contact with skin or if inhaled

Obtain special instructions before use. Do not handle until all safety precautions have been read and Precautionary Statements:

Obtain special instructions before use. Do not handle until all safety precautions have been read and understood. Wash hands thoroughly after handling. IF exposed or concerned: Get medical advice/attention. Store locked up. Wear protective gloves/protective clothing/eye protection/face protection. IF ON SKIN: Wash with plenty of soap and water. Avoid breathing dust/fume/gas/mist/vapours/spray. IF SWALLOWED: Call a POISON CENTER or doctor/physician if you feel unwell. IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists: Get medical advice/attention. Store in a well-ventilated place. Keep container tightly closed. IF INHALED: Remove victim to fresh air and the protein a profetion comportable for breathing. keep at rest in a position comfortable for breathing. Call a POISON CENTER or doctor/physician if you feel unwell. Use only outdoors or in a well-ventilated area. Dispose of contents/container in accordance

with Local, State, Federal and Provincial regulations. If skin irritation occurs: Get medical advice/attention. Take off contaminated clothing and wash it before reuse.

Emergency Overview: This product is intended for therapeutic use only when prescribed by a physician. Potential adverse

reactions from prescribed doses and overdoses are described in the package insert.

Route of Exposure: Inhalation Ingestion Eye contact Skin Absorption. Injection.

Potential Health Effects:

Eve: Contact with eyes may cause irritation.

May cause skin irritation.

Inhalation: May cause irritation of respiratory tract.

Ingestion: May cause irritation.

There is no known antidote for overdosage with decitabine for injection. Higher doses are associated Signs/Symptoms:

with increased myelosuppression including prolonged neutropenia and thrombocytopenia. Standard

supportive measures should be taken in the event of an overdose.

SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS

Chemical Name **Ingredient Percent** CAS# EC Num. Decitabine 2353-33-5 50 mg by weight 219-089-4 7778-77-0 231-913-4 Potassium phosphate monobasic 7.21 mg/g by weight Sodium hydroxide 1310-73-2 1.23 mg/g by weight 215-185-5 200-835-2 Acetonitrile 75-05-8 29 (w/w) %

SECTION 4: FIRST AID MEASURES

Eye Contact: Immediately flush eyes with plenty of water for at least 15 to 20 minutes. Ensure adequate flushing of

the eyes by separating the eyelids with fingers. Get immediate medical attention

Immediately wash skin with plenty of soap and water for 15 to 20 minutes, while removing contaminated clothing and shoes. Get medical attention if irritation develops or persists. Skin Contact:

If inhaled, remove to fresh air. If not breathing, give artificial respiration or give oxygen by trained personnel. Seek immediate medical attention. Inhalation:

Ingestion: If conscious, flush mouth out with water immediately. Call a physician or poison control center

immediately. Do not induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an unconscious person.

Other First Aid: For Adverse Event Information, please call (800) 551-7176.

SECTION 5: FIRE FIGHTING MEASURES

Flash Point: Not established. Flash Point Method: Not established. Auto Ignition Temperature: Not established. Lower Flammable/Explosive Limit: Not established. Upper Flammable/Explosive Limit: Not established.

Evacuate area of unprotected personnel. Use cold water spray to cool fire exposed containers to Fire Fighting Instructions:

minimize risk of rupture. Do not enter confined fire space without full protective gear. If possible, contain fire run-off water.

Extinguishing Media: Use alcohol resistant foam, carbon dioxide, dry chemical, or water fog or spray when fighting fires

involving this material.

Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

Protective Equipment: As in any fire, wear Self-Contained Breathing Apparatus (SCBA), MSHA/NIOSH (approved or equivalent)

Hazardous Combustion

Byproducts:

Thermal decomposition generates: Carbon oxides (CO, CO2). Hydrogen chloride. Chlorine oxides.

Halogenated Compounds.

SECTION 6: ACCIDENTAL RELEASE MEASURES

Personal Precautions: Evacuate area and keep unnecessary and unprotected personnel from entering the spill area

Avoid personal contact and breathing dust. Use proper personal protective equipment as listed in

Section 8

Environmental Precautions: Avoid runoff into storm sewers, ditches, and waterways.

Methods for containment: Contain materials by a method that controls dust generation.

Methods for cleanup: Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum

should be used to clean spills of dry solids. Clean spill area thoroughly.

SECTION 7: HANDLING and STORAGE

Handling: Wash hands and other exposed areas with mild soap and water before eating, drinking or smoking and

when leaving work. When handling pharmaceutical products, avoid all contact and inhalation of dust. Use with adequate ventilation. Use only in accordance with directions.

Storage: Store at 25°C (77°F); excursions permitted to 15 to 30°C (59 to 86°F). [See USP Controlled Room

Keep container closed when not in use. Store in a dry, cool and well-ventilated place. Keep/Store away

from direct sunlight, extremely high or low temperatures and incompatible materials. Containers which

are opened should be properly resealed and kept upright to prevent leakage.

Work Practices: Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety

Hygiene Practices: Wash thoroughly after handling. Avoid contact with eyes and skin. Avoid inhaling dust.

SECTION 8: EXPOSURE CONTROLS, PERSONAL PROTECTION

General ventilation is sufficient if this product is being used in a controlled medical setting (clinic, **Engineering Controls:**

hospital, medical office) for its sole intended parenteral (injection) purpose. Otherwise, use appropriate engineering control such as process enclosures, local exhaust ventilation, or other engineering controls including use of a biosafety cabinet / fume hood to control airborne levels below recommended

exposure limits.

Eye/Face Protection: Chemical splash goggles. Wear a face shield also when splash hazard exist.

Skin Protection Description: Protective laboratory coat, apron, or disposable garment recommended.

Wear appropriate protective gloves. Consult glove manufacturer's data for permeability data. Nitrile rubber or natural rubber gloves are recommended. Hand Protection Description:

Respiratory Protection: No personal respiratory protective equipment is normally required when this product is being

used/administered by a licensed healthcare practitioner (i.e. an end-user such as a clinician / doctor / nurse) for its sole intended parenteral (injection) purpose in a controlled medical setting. The need for respiratory protection will vary according to the airborne concentrations and environmental conditions. A NIOSH approved air-purifying respirator with an organic vapor cartridge or canister may be permissible

under certain circumstances. Consult the NIOSH web site

(http://www.cdc.gov/niosh/npptl/topics/respirators/) for a list of respirator types and approved suppliers.

Other Protective: Consult with local procedures for selection, training, inspection and maintenance of the personal

protective equipment.

EXPOSURE GUIDELINES

Sodium hydroxide:

Guideline ACGIH: TLV-TWA: 2 mg/m3

<u>A cetonitrile</u>:

TLV-TWA: 20 ppm

Guideline ACGIH: Guideline NIOSH: TLV-TWA: 20 ppm

SECTION 9: PHYSICAL and CHEMICAL PROPERTIES

Physical State: Crystalline powder.

Color: White

Boiling Point: Not established. Melting Point: Not established. Solubility: No data available. Not established. Vapor Density: Vapor Pressure: Not established. Percent Volatile: Not established. pH: 3.5 - 6.5

Molecular Formula: Mixture Molecular Weight: Variable

Flash Point: Not established. Flash Point Method: Not established. Auto Ignition Temperature: Not established.

SECTION 10: STABILITY and REACTIVITY

Chemical Stability: Stable under normal temperatures and pressures.

Hazardous Polymerization: Not reported.

Conditions to Avoid: Direct sunlight, extremely high or low temperatures, and incompatible materials.

Incompatible Materials: Strong acids, strong bases, strong oxidizers. Reducing agents. Water reactive materials.

SECTION 11: TOXICOLOGICAL INFORMATION

Acute Toxicity: Eye, skin, and respiratory irritation may occur.

Acute Effects: Eye, skin, and respiratory irritation may occur.

Chronic Effects: None known.

Reproductive Toxicity: Presumed human reproductive toxicant

Decitabine :

RTECS Number: XZ3012000

Ingestion: LD50-Oral-Rat 1290 mg/kg

Potassium phosphate monobasic:

RTECS Number: TC6615500

Skin: LD50 Dermal - Rabbit - > 4,640 mg/kg Inhalation: LC50 Inhalation - Rat - male and female - 4 h - > 0.83 mg/l

Inaestion: LD50 Oral - Rat - female - > 2,000 mg/kg

Sodium hydroxide:

RTECS Number: WB4900000

Acetonitrile:

AL7700000 RTECS Number:

Skin: LD50 Dermal - Rabbit - male and female - > 2,000 mg/kg Inhalation: LC50 Inhalation - Mouse - male and female - 4 h - 6.022 mg/l

Ingestion: LD50 Oral - Mouse - male and female - 617 mg/kg

SECTION 12: ECOLOGICAL INFORMATION

Ecotoxicity: No ecotoxicity data was found for the product.

Environmental Stability: No environmental information found for this product.

SECTION 13: DISPOSAL CONSIDERATIONS

Waste Disposal: Dispose of in accordance with Local, State, Federal and Provincial regulations.

SECTION 14: TRANSPORT INFORMATION

DOT Shipping Name: Not Regulated. DOT UN Number: Not Regulated.

IATA Shipping Name: Non regulated. IATA UN Number: Non regulated.

IMDG UN Number: Non regulated. IMDG Shipping Name: Non regulated.

SECTION 15: REGULATORY INFORMATION

Decitabine:

EC Number: 219-089-4

Potassium phosphate monobasic:

EC Number: 231-913-4

Sodium hydroxide:

EC Number: 215-185-5

Acetonitrile:

EC Number: 200-835-2

SECTION 16: ADDITIONAL INFORMATION

HMIS Ratings:

HMIS Health Hazard: HMIS Fire Hazard: HMIS Reactivity: HMIS Personal Protection:

SDS Creation Date: May 30, 2019 SDS Revision Date: October 14, 2019 SDS Revision Notes: "New formulation"

Disclaimer:

The information contained herein pertains to this material. It is the responsibility of each individual party to determine for themselves the proper means of handling and using these materials based on their purpose and intended use. Fresenius-Kabi assumes no liability resulting from the use of or reliance upon the information contained in this material safety data sheet. This material safety data

sheet does not constitute the guaranty or specifications of the product.

Copyright© 1996-2018 Enviance. All Rights Reserved.